Bronte Capital Management Pty Ltd. Sells 1,701 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Bronte Capital Management Pty Ltd. cut its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 0.6% during the 4th quarter, HoldingsChannel reports. The firm owned 281,528 shares of the financial services provider’s stock after selling 1,701 shares during the period. iShares Biotechnology ETF comprises 3.7% of Bronte Capital Management Pty Ltd.’s investment portfolio, making the stock its 11th largest position. Bronte Capital Management Pty Ltd.’s holdings in iShares Biotechnology ETF were worth $38,246,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in IBB. Jacobi Capital Management LLC raised its stake in shares of iShares Biotechnology ETF by 3.7% during the third quarter. Jacobi Capital Management LLC now owns 2,539 shares of the financial services provider’s stock valued at $310,000 after acquiring an additional 91 shares during the last quarter. PFG Investments LLC raised its holdings in iShares Biotechnology ETF by 4.8% during the 3rd quarter. PFG Investments LLC now owns 2,013 shares of the financial services provider’s stock worth $246,000 after purchasing an additional 93 shares during the last quarter. Huntington National Bank increased its position in shares of iShares Biotechnology ETF by 7.4% during the third quarter. Huntington National Bank now owns 1,450 shares of the financial services provider’s stock worth $177,000 after buying an additional 100 shares during the period. HB Wealth Management LLC raised its stake in iShares Biotechnology ETF by 5.9% during the fourth quarter. HB Wealth Management LLC now owns 1,892 shares of the financial services provider’s stock worth $257,000 after buying an additional 105 shares during the last quarter. Finally, Peterson Wealth Management lifted its holdings in iShares Biotechnology ETF by 2.9% in the third quarter. Peterson Wealth Management now owns 3,743 shares of the financial services provider’s stock valued at $458,000 after buying an additional 106 shares during the period. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Trading Up 0.6 %

IBB stock traded up $0.83 during mid-day trading on Thursday, reaching $133.42. The company’s stock had a trading volume of 981,442 shares, compared to its average volume of 1,783,524. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $141.16. The business’s 50 day moving average price is $133.20 and its 200 day moving average price is $130.36.

iShares Biotechnology ETF Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 27th. Investors of record on Friday, March 22nd were paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.38%. The ex-dividend date was Thursday, March 21st.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.